All In Biotech

Drug Trial Radar · NCT00415805

Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent

A Pilot, Open-label, Multicenter Intra-individual Comparison of Multihance and Vasovist for Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of Renal Arteries

Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

39

Actual

Start

Dec 2006

Primary completion

Dec 2008

Study completion Feb 2009

Sponsor

Lead sponsor
Bracco Diagnostics, IncIndustry
Sponsor type
Industry
First posted
Dec 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market. Since the study is explorative and designed to provide preliminary information for consideration for a future larger study, sample size is not based on statistical assumptions.

Conditions

  • Steno-occlusive Disease

Interventions

  • MultihanceDrug

    0.5 Molar, single injection at 0.2 mL/kg

  • vasovistDrug

    0.25 molar single injection 0.03 ml/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and specificity compared to DSATime frame: post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bracco Imaging, S.p.A

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.